COL18A1 and hepatocellular carcinoma: Our previous study suggest that CSP I-plus modified recombinant human Endostatin (rEndostatin, Endostar) could specifically target to hepatocellular carcinoma cells, to achieve higher local concentrations and showed higher anti-angiogenic capability on HUVECs tube formation assay and chick embryo CAM assay, when compared with unmodified rEndostatin given at similar doses25.